Shorter telomeres may mark fatty liver disease risk, but evidence is uneven
An observational review linked shorter telomeres in white blood cells with metabolic dysfunction-associated steatotic liver disease, or MASLD. Findings varied by study design and clinical subgroup.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Shorter telomeres were associated with a greater risk of MASLD and possibly more severe progression, particularly in studies that followed people over time. However, findings were inconsistent in studies measuring people at a single point. These associations do not establish a cause of liver disease or a clinically useful test.
Few high-quality studies were available. Substantial differences between studies, publication bias, and methodological limitations weaken confidence in the associations. The abstract provides no numerical effect estimates or established clinical use.
Study design changed the picture
Cohort studies generally connected shorter white blood cell telomeres with later disease. Cross-sectional studies gave less consistent results, showing why a measurement taken once may tell a different story from changes tracked over time.
Length and change are different
In a subgroup with diabetes, cross-sectional data showed longer telomeres among people with MASLD. The abstract also highlighted faster telomere shortening in longitudinal evidence, underscoring that baseline length and subsequent change are different measurements.
The original publication
Telomere length and metabolic dysfunction-associated steatotic liver disease risk and progression: A systematic review and meta-analysis.
Sun C, Qiu P, Huang S et al.
Exp Gerontol · 2026
- PubMed ID
- 41544829
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.